View source for Potent monoclonal antibody–mediated neutralization of a divergent Hendra virus variant

'''Authors:''' Zhaoqian Wang, Ha V. Dang, Moushimi Amaya, Yan Xu, Randy Yin, Lianying Yan, Andrew C. Hickey, Edward J. Annand, Bethany A. Horsburgh, Peter A. Reid, Ina Smith, John-Sebastian Eden, Kai Xu, Christopher C. Broder, David Veesler

'''Year:''' 2022

'''Journal:''' Not specified in the text

'''DOI:''' 10.xxxx/xxxxx or null (not provided in the text)

'''PMID:''' PMID or null (not provided in the text)

=== Summary ===
This paper studies a new variant of Hendra virus (HeV-g2) that has unprecedented genetic divergence and identifies it in horses and flying fox species in Australia. The researchers demonstrate that HeV-g2 shares a conserved receptor tropism with prototypic HeV and can be potently neutralized by a panel of monoclonal antibodies recognizing the G and F glycoproteins.

=== Key Findings ===
* The study identifies a new Hendra virus variant (HeV-g2) with unprecedented genetic divergence
* HeV-g2 shares a conserved receptor tropism with prototypic HeV
* A panel of monoclonal antibodies recognizing the G and F glycoproteins potently neutralizes HeV-g2– and HeV G/F– mediated entry into cells

=== Methodology ===
* '''Study Type:''' Not specified in the text
* '''Sample Size:''' Two fatally diseased horses and two flying fox species studied
* '''Geographic Focus:''' Regions of Australia
* '''Time Period:''' Not specified in the text

=== Topics ===
Virology, Immunology

=== Relevance ===
Understanding receptor usage and antigenic properties of HeV-g2 is urgently required to guide One Health biosecurity

=== Source ===
View the entire paper: [[File:pnas.202122769.pdf]]